Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Patients who are at least 18 years of age and have a type of cancer known as advanced
non-small cell lung cancer may be eligible for this study if they meet all of the
inclusion/exclusion criteria.
Background: The standard treatment for patients with advanced non-small cell cancer is
chemotherapy. The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is
commonly used as the first treatment. Unfortunately, standard treatment with chemotherapy
only shrinks the cancer in about 30% of patients that receive it. There is no way to predict
who will or won't benefit from this treatment. The researchers at the University of Michigan
would like to determine if the genes of the lung cancers in patients enrolled in this study
will help predict whether or not the tumors shrink when exposed to standard chemotherapy. The
goal is to find a set of lung cancer genes that will predict successful treatment with
carboplatin and paclitaxel in patients with non-small cell lung cancer.
The actual treatment, carboplatin and paclitaxel, involved in this study is not experimental.
The experimental aspect of this study is the identification of predictors of response to
treatment. To do this, it would require a sample of your cancer. If your initial surgery or
biopsy was done at the University of Michigan, we may already have an adequate sample of your
cancer that could be used for this research. In that case, we are asking for your permission
to use this sample for this study. However, if you meet all eligibility criteria and agree to
participate in this research study and an adequate sample is not available, you will need to
undergo another biopsy procedure for us to obtain a sample of your cancer. Obtaining a tumor
sample is the most crucial part of this research study.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center